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LETTER
3-Anhydro-6-hydroxy-ophiobolin A displays
high in vitro and in vivo efﬁcacy against
inﬂuenza A virus infection
Dear Editor,
Inﬂuenza A virus (IAV) is an enveloped negative-strand RNA
virus containing eight RNA segments that belongs to the
family Orthomyxoviridae and can cause acute respiratory
infection in humans and animals. Although vaccination is
one of the major means for prophylaxis of inﬂuenza virus
infection, a particular inﬂuenza vaccine only confers pro-
tection for no more than a few years. In addition, the out-
break of novel inﬂuenza infection cannot be predicted (Gao
et al., 2013). Thus, vaccine is unable to provide immediate
protection against sudden inﬂuenza outbreaks with unknown
identity. Development of antiviral drugs for therapeutic
treatment is an important strategy to reduce the duration and
severity of inﬂuenza. However, more and more drug-resis-
tant inﬂuenza virus strains are emerging due to its antigenic
drift or antigenic shift, which increases the need for new
antivirals.
Over the past decades, progresses have been made in
developing small molecule compounds for treatment of
inﬂuenza viral infection. For example, previous experiments
demonstrated that the novel NF-kappaB inhibitor SC75741
signiﬁcantly protected mice against infection with highly
pathogenic avian inﬂuenza A viruses (HPAIV) of the H5N1
and H7N7 subtypes (Haasbach et al., 2013). The MEK
inhibitor U0126, targeting the intracellular Raf/MEK/ERK
signaling pathway, is able to suppress propagation of both
the 2009 pandemic IAV and HPAIV in vitro and in vivo
(Droebner et al., 2011). Moreover, two identiﬁed novel anti-
IAV agents, obatoclax and gemcitabine possess broad-
spectrum antiviral activity. Obatoclax can inhibit IAV uptake
and gemcitabine can suppress viral RNA transcription and
replication (Denisova et al., 2012; Planz, 2013). Inﬂuenza
virus utilizes cellular machinery for the replication and
assembly of viral components and the release of progeny
virions. Recent genome-wide RNAi screening has identiﬁed
several host genes and molecular networks crucial for the
viral replication (Karlas et al., 2010; Watanabe et al., 2010),
providing potential ways for anti-inﬂuenza therapy.
In our ongoing search for new bioactive compounds from
fungi, we have recently reported 3-anhydro-6-hydroxy-
ophiobolin A (L435-3), a new sesterterpene with antibacterial
activities from the phytopathogenic fungus Bipolaris oryzae
(Wang et al., 2013). In this study, we further examined the
potential anti-inﬂuenza activity of L435-3 in vitro and in vivo.
First, A549 cells were infected with inﬂuenza virus strain
WSN virus and then treated with or without L435-3. We
found that treatment with L435-3 could inhibit the IAV repli-
cation at very low concentration (Fig. 1A), indicating that
L435-3 may be a potential therapeutic agent for treatment of
inﬂuenza virus infections.
To further conﬁrm the inhibitory effect of L435-3 on IAV
infection, we performed several experiments using A549 and
MDCK cells infected with WSN or PR8 virus. As shown in
Table S1, L435-3 displayed high activity against WSN or
PR8 virus infection in MDCK cells, although its activity is
lower than that of zanamivir. Then A549 cells were infected
with WSN at a multiplicity of infection (MOI) of 0.2, and
treated with 0.5 μM L435-3 at 1 h post-infection. Indeed, 0.5
μM L435-3 showed little cytotoxicity to A549 cells, and the
inﬂuenza virus titers were markedly reduced by L435-3
treatment (Fig. 1B and 1C). Using Western blotting, we fur-
ther conﬁrmed that L435-3 treatment signiﬁcantly inhibited
inﬂuenza virus replication, since the levels of both viral HA
and NP were markedly reduced in WSN-infected A549 cells
treated with L435-3 (Fig. 1D). Together, these experiments
demonstrate that L435-3 is a potent inhibitor of IAV replica-
tion in host cell.
Next, we investigated the anti-inﬂuenza virus activity of
L435-3 in vivo. To this end, Balb/c mice were separated into
four groups (12 mice/each group). Two groups of mice were
infected with WSN and then inoculated intranasally with
L435-3 (0.3 mg/kg/mouse) or mock control. The other two
groups of mice were only treated with L435-3 or mock con-
trol. All mice were monitored for body weight change and
survival rate. As expected, WSN challenge resulted in
obvious ﬂu symptoms in all mice on day 2 post-infection.
However, the symptoms were remarkably less severe in
L435-3 treated group (Fig. 1E). The mice without L435-3
treatment showed a more weight loss as compared to L435-
3 treated group during the IAV infection (Fig. 1F). To further
determine the efﬁcacy of L435-3, we compared the mortality
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between these groups over a 14-day infection period. The
results displayed that the control group mice began to die on
day 4 post-infection and all mice died within 6 days after
infection. However, only 50% mice died in L435-3 treated
group over the whole time course. Of note, no mice died in
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Figure 1. L435-3 inhibits IAV replication in vitro and in vivo. (A) A549 Cells were infected with WSN viruses and further treated
with different concentrations of L435-3 for 12 h. Progeny virus titer was determined by plaque assay. (B and C) A549 cells infected
with WSN viruses were mock treated or treated with L435-3 (0.5 μmol/L) for indicated times. The supernatants of cell culture were
examined for the viral titers by hemagglutinin assay (B) and plaque assay (C). (D) A549 cells infected with WSN virus were mock
treated or treated with L435-3 (0.5 μmol/L), then the cells were harvested at the indicated times, and followed by analysis of Western
blotting with indicated antibodies. (E) BALB/c mice infected with WSN viruses (5 × 104 PFU/mouse) were mock treated or inoculated
intranasally with L435-3 (0.3 mg/kg). Shown is a representative photograph of the two differently treated mice. (F) Shown are body
weight changes of control mice, WSN and/or L435-3 treated mice. *P < 0.05, difference between WSN+ L435-3− and WSN+ L435-3+
groups by daily examination. (G) Survival rate of control mice, WSN and/or L435-3 treated mice. The mice were monitored for up to
14 d. Survival curves were compared using a log-rank test (GraphPad Prism 5). **P < 0.01, difference between WSN+ L435-3- and
WSN+ L435-3+ groups. (H) WSN-infected mice were mock treated or treated with L435-3 (0.3 mg/kg) for 3 days. Then the mice were
sacriﬁced and viral titers in the lungs were measured by plaque assay. (I) WSN-infected mice were treated with L435-3 as described
in (H). Then the lungs were homogenized, followed by analysis of Western blotting with indicated antibodies. * P < 0.05, **P < 0.01.
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To determine whether L435-3 affected pathological
changes induced by WSN infection, the mice were sacriﬁced
and dissected on day 4 post-infection. We observed that the
pulmonary lesions in the L435-3 treated group were less
than that in the control group without L435-3 treatment.
Additionally, the atrophy of spleens and thymuses in L435-3
treated group was less severe than that in the control group
(Fig. S1A). Pathohistological analysis revealed that the lung
tissues in L435-3 treated group displayed less inﬂammation,
interstitial edema, and lung consolidation than the control
group (Fig. S1B). The spleen tissues in L435-3 treated group
showed that the areas of white pulp were increased, and
there were clearer boundaries between white pulps and red
pulps than the control group (Fig. S2C). Together, these
observations suggest that L435-3 has a profound inhibitory
effect on WSN infection of mice.
Because L435-3 showed considerable protection against
IAV infection in mice, we further determined whether L435-3
inhibited the viral replication in mice. Consistent with our
in vitro data presented above, treatment with L435-3 signif-
icantly reduced the viral titers in the lungs of WSN-infected
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Figure 2. L435-3 treatment increases the expression of type III interferons and ISGs both in A549 cells and in mice infected
with IAV. (A) WSN-infected A549 cells were treated with or without L435-3 (0.5 μmol/L) for 6 h and 12 h, and then the mRNA levels of
indicated genes were analyzed by RT-PCR. (B and C) WSN-infected A549 cells were treated with or without L435-3 as described in
(A). The mRNA levels of IL28 (B) and IL29 (C) were analyzed by quantitative real-time PCR. (D) WSN-infected BALB/c mice were
treated with or without L435-3 (0.3 mg/kg/mouse) for 3 days. Then the mice were sacriﬁced, and the mRNA levels of indicated genes
in mouse lung were detected by RT-PCR. (E, F and G) WSN-infected BALB/c mice were treated as described in (D). The mRNA
levels of IL28 (E), ISG15 (F) and ISG20 (G) in mouse lungs were detected by quantitative real-time PCR. *P < 0.05.
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markedly lower in the L435-3 treated group than those in the
control group (Fig. 1I). Collectively, these results reveal that
L435-3 signiﬁcantly impairs the viral replication in vivo during
the IAV infection of mice.
In an attempt to explore the mechanisms by which L435-3
inhibits inﬂuenza virus replication, cDNA microarray analysis
was performed to determine the differentially expressed
genes in IAV-infected A549 cells in response to L435-3
treatment (http://www.ncbi.nlm.nih.gov/geo/; GenBank
accession number GSE58741). Treatment with L435-3
resulted in up-regulation of 1027 genes, and down-regula-
tion of 1047 genes in IAV-infected A549 cells. Interestingly,
we found that many genes were involved in innate immunity
and inﬂammatory response.
To verify the cDNA microarray data, RT-PCR and quan-
titative real-time PCR were employed. We observed that the
expressions of IL28 and IL29 were markedly up-regulated by
L435-3 treatment at 6 or 12 h after WSN infection (Fig. 2A–
C). Moreover, the expression levels of several interferon-
stimulated genes (ISGs) were measured by quantitative real-
time PCR. As shown in Fig. S2, the expressions of ISG15,
ISG20 and OASL were signiﬁcantly increased in WSN-in-
fected A549 cells treated with L435-3 as compared to the
control.
Next, we tested whether L435-3-mediated inhibition of
IAV replication in mice was caused by increased expression
of interferons. Consistent with in vitro observations pre-
sented above, L435-3 treatment led to an increase in
expression levels of IL28, ISG15 and ISG20 in WSN infected
mice by both RT-PCR (Fig. 2D) and quantitative real-time
PCR (Fig. 2E–G). These results suggest that L435-3 inhibits
IAV replication likely through increasing the production of
type III interferons and some ISGs.
Inﬂuenza virus is still a threat to public health and world
economy. Although two classes of antiviral agents targeting
M2 or NA are used in the clinical treatment of inﬂuenza viral
infection, an increasing number of drug-resistant viruses
have emerged (Regoes and Bonhoeffer, 2006; Cheng et al.,
2009; Hurt et al., 2009; Moscona, 2009). Therefore, the
development of novel anti-IAV drug has become an urgent
task to combat against inﬂuenza viruses. In this study, we
identiﬁed L435-3, a new derivative of ophiobolins A from
fungus B. oryzae, as a potent inhibitor that strongly sup-
presses IAV infection.
Ophiobolins are a group of phytotoxic sesterterpenoids
and secondary metabolites produced by the phy-
topathogenic fungi that attack maize, rice, and sorghum.
They possesses a broad spectrum of inhibitory activity
against fungi, bacteria, and nematodes, and cytotoxic
activity against cancer cells (Au et al., 2000; Phuwapraisir-
isan et al., 2007; Yang et al., 2012; Wang et al., 2013). As a
derivative of ophiobolins, L435-3 has a good antimicrobial
activity against Bacille Calmette-Guerin, Bacillus subtilis,
Staphylococcus aureus, and methicillin-resistant Staphylo-
coccus aureus. Moreover, it exhibits potent antiproliferative
activity against K562 and HepG2 cell lines (Wang et al.,
2013). In this study, our results represent the ﬁrst report of
ophiobolin derivative L435-3 that displays high in vitro and
in vivo efﬁcacy against IAV infection. However, whether this
compound possesses activity against other viruses remains
to be further determined.
Our study has also addressed the mechanism by which
L435-3 may affect pathogenesis of inﬂuenza infections.
The microarray analysis showed that L435-3 treatment
could induce higher level expressions of type III IFNs and
several ISGs both in cell line and mice during the IAV
infection, and thereby established an antiviral state in host.
This ﬁnding was further conﬁrmed by RT-PCR and real-
time PCR.
In summary, our results identiﬁed L435-3 as a novel and
potent inhibitor against IAV infection through enhancing the
host immunity in vitro and in vivo. However, there might exist
other mechanisms by which L435-3 defends against IAV
infection, and the precise mechanisms underlying function of
L435-3 remain to be better understood. As a promoter of
host immune responses to IAV infection, L435-3 can likely
inhibit the infection of inﬂuenza viruses that are resistant to
oseltamivir and/or amantadine. Therefore, L435-3 may be a
valuable candidate for development of a novel anti-inﬂuenza
agent.
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